The very first CT to lay the groundwork of treating HCC with a multi-target receptor tyrosine kinase inhibitor (RTKI) in HCC was the SHARP trial, which proved that sorafenib, which blocks VEGFR, PDGFRα, and RAF kinases, significantly extends progression-free and overall survival in comparison to the placebo (Table 1) [5]. The gene discussed is PDGFRA; the disease is hepatocellular carcinoma.